Prostate Cancer: Imaging and Therapy Options from an Oncology Perspective
Published Date: October 14, 2025
Prostate Cancer: Imaging and Therapy Options from an Oncology Perspective
Prostate cancer care is moving fast right now—and not just in big academic centers. Advanced imaging and theranostic options are showing up in community oncology more and more, and that shift is changing how teams think about staging, recurrence, and treatment planning. This overview connects the dots between the imaging tools that are increasingly part of everyday practice (including when each modality is most helpful) and the real-world decisions that follow from what you find.
Just as importantly, it speaks to the reality many teams are navigating: what’s “ideal” on paper doesn’t always match what’s feasible in clinic. Coverage and local availability can shape imaging choices, and therapy advances are prompting new sequencing and coordination conversations—especially as practices think through readiness, monitoring, and multidisciplinary workflow.
Key highlights
- PSMA PET: clinical value vs. real-world access
- mpMRI and PSMA PET: distinct roles, better decisions
- Tracer choice: logistics matter as much as clinical fit
- A new PSMA imaging option entered the mix in 2025
- A major radioligand therapy label update is shifting sequencing discussions
- What it takes to implement in community practice: pathways, triggers, teamwork
Read the full article in Oncolytics Today for a closer look at PSMA PET access, tracer selection, and how radiopharmaceutical therapies are influencing sequencing decisions.
Juliet Roldan, MBA, CNMT, RT(CT)ARRT